OM
Outset Medical, Inc.
Price as of Jul 20, 2026
OM earnings
Outset Medical, Inc. earnings
Reported EPS and revenue history, upcoming estimates and available earnings-call summaries.
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.79 | $-0.83 | -5.1% | $28M | -3.5% |
| Feb 11, 2026 | $-0.45 | $-1.09 | -143.1% | $29M | -0.1% |
| Aug 6, 2025 | $-1.76 | $-0.84 | +52.3% | $31M | +6.8% |
| May 7, 2025 | $-0.97 | $-3.24 | -234.0% | $30M | +7.0% |
| Feb 19, 2025 | $-6.45 | $-5.55 | +14.0% | $29M | +3.5% |
| Feb 21, 2024 | $-9.15 | $-8.85 | +3.3% | $31M | +0.4% |
| Aug 2, 2023 | $-10.94 | $-10.34 | +5.5% | $36M | -4.0% |
| May 3, 2023 | $-10.34 | $-10.79 | -4.4% | $33M | +5.4% |
| Feb 13, 2023 | $-11.39 | $-10.64 | +6.6% | $32M | +3.5% |
| May 4, 2022 | $-9.90 | $-10.04 | -1.4% | $31M | +1.5% |
| Feb 16, 2022 | $-10.04 | $-11.54 | -14.9% | $28M | +6.5% |
| Nov 3, 2021 | $-9.75 | $-8.85 | +9.2% | $26M | +4.6% |
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- First quarter reflected consistent execution across console utilization, new customer additions, gross margin expansion, and disciplined cash management. - Variability in capital order timing impacted capital sales but confidence in growth plan remains. - Upcoming launch of next generation Tableau, deep sales pipeline, and new commercial leader Derek Elliott. - Key wins during the quarter with successful go-live implementations. - Service and implementation teams extend clinical expertise. - Well prepared for initial transition to next-generation Tableau later in the quarter, which meets FDA cybersecurity requirements and has strong reception in early customer discussions. - Reiterate strong cash position and focus on reaching profitability, with progress in supply chain, manufacturing, service organization, and partnerships.
Guidance
- Continue to expect revenue to be in the range of $125 to $130 million, a 5% to 9% increase over 2025, with majority of growth in third and fourth quarters. - Non-GAAP gross margins expected to be in the low to mid 40% range for the full year, balancing console shipment and consumables mix factors.
Segment performance
Revenue in the first quarter was $27.9 million, down slightly from the fourth quarter due to capital sales lumpiness. Product revenue was $18.6 million, down 13%. Capital sales were $5.4 million, consumable sales were $13.2 million, and service and other revenue was $9.3 million, up 10%. Non-GAAP gross margin expanded 620 basis points to 43.8% for the quarter. Product gross margin increased 400 basis points to 52.4%. Service and other gross margin was 26.7%, increasing sequentially and growing over 1,600 basis points compared to the prior year.
Analyst Q&A
Q: Rick Wise asked about capital order variability and quarterly phasing.
A: Leslie Trigg and Renee Guyetta responded that capital order lumpiness is around close timing, with delayed deals expected to close in Q2-Q4, Q2 expected to be a modest step up with sequential step up in each quarter.
Q: Colin Clark asked about confidence in large orders in the pipeline.
A: Leslie Trigg said confidence is informed by deal staging, historical data on probability of close, and next-generation Tableau launch as a demand driver.
Q: Colin Clark also asked about next-gen system accelerating trade-in timelines and bi-directional integration.
A: Leslie Trigg said next-gen system could accelerate trade-in timelines and there's potential for bi-directional data transfer with EMR, which would be an incremental revenue opportunity for recurring revenue.
Earnings history is derived from company filings and calendar data. Call summaries are grouped by reporting period. Latest covered event: 2026-08-05.